Rodin Therapeutics (@Rodintx) header
Rodin Therapeutics (@Rodintx) profile picture
Cambridge, MA
Joined March 2016
It was an honor to attend the Society for Neuroscience's 49th annual meeting alongside 30,000 peers from more than 70 countries. #SfN19 @SfNtweets
5
The Rodin team will present our poster, "Characterization of an HDAC corepressor complex inhibitor for the treatment of FTD-GRN," at the @SfNtweets annual meeting. Join us on Monday, Oct. 21 at the Alzheimer's Disease and Strategies session. #SfN19
2
6
Rodin collaborator Hayel Tuncel will be presenting [11C]UCB-J data at the @officialEANM Conference on Sunday. We are happy to help progress the science of synaptic density imaging and look forward to the discussions. #EANM19
1
4
As our controller and director of Rodin's financial organization, Sari Epstein provides in-depth financial analyses and ensures the integrity of our information systems.
4
We recently held a company retreat up in Stowe, VT to align on our goals and to do some outdoor team building. We are energized for a busy fall!
11
Ajim Tamboli, our CFO, was a biotech investor, analyst and advisor before he co-founded Endurant Capital Management. His experience will help us advance our lead program and build our pipeline. Read more: https://xitter.gq/t.co/mGdocXjnlm
10
Tomorrow on World #Alzheimers Day, we unite with patients, families and organizations in the global movement to help those affected by Alzheimer's and other forms of dementia. Learn more: worldalzmonth.org/ #LetsTalkAboutDementia
5
Two of our team members were in New London, CT this weekend to participate in the local 2019 Walk to End Alzheimer’s. We are proud to take part in the fight to #ENDALZ and raise funds for #Alzheimers care, support and research. #Walk2EndAlz
1
8
We're pleased to join the @MorganStanley Global Healthcare Conference in New York today where our CEO Adam Rosenberg will present on our scientific and clinical progress and milestones.
11
Nathan Fuller, our senior director of chemistry, will be sharing the story of the discovery of Rodin's HDAC-CoREST inhibitors at the 20th SCI/RSC Medicinal Chemistry Symposium in Cambridge, UK tomorrow. Meeting agenda: soci.org/events/20th-scirsc-…
1
6
Our CEO Adam Rosenberg will present tomorrow at the 21st annual @HCWCO Global Investment Conference. We look forward to many productive conversations. Read more: rodmanevents.com #HCWCO
6
Our team will be presenting at the 2019 @WellsFargo Healthcare Conference in Boston today. Join us for Rodin's company presentation and one-on-one meetings. #BiotechNews
5
#ICYMI: We've officially settled into our Boston headquarters and look forward to many productive discussions in our new space! https://xitter.gq/t.co/lvMCWbeGmB
8
Nathan Fuller, senior director of chemistry, guided development of our lead compound, RDN-929, and co-authored our scientific paper demonstrating the efficacy of our highly selective CoREST-HDAC inhibitors in preclinical models. Read the paper: https://xitter.gq/t.co/ml0VRntsPu
1
15
Today we announced the appointment of Ajim Tamboli as chief financial officer. Ajim joins Rodin with more than 20 years of experience as a healthcare investor and advisor. Read more: https://xitter.gq/t.co/mGdocXjnlm
1
3
3
10
Meet Amy DiRico, our senior director of clinical operations. Armed with a strong background in #clinicaltrial management, Amy plays a critical role in overseeing our Phase 1 program, including our recent successful SAD/MAD trial of RDN-929. Trial results: https://xitter.gq/t.co/lv1qBgL943
1
10
Our own Steve Sweeney is at the @alzassociation conference in L.A. presenting data supporting the use of [11C]UCB-J to measure synaptic density in longitudinal clinical trials. He's in South Hall GH (poster # P2-375). Abstract here: https://xitter.gq/t.co/XMYqEtX6mM #AAIC19
The Rodin team is moving! Beginning on July 17, find us at 101 Huntington Ave near the Prudential Center.
1
7
We're looking forward to attending tomorrow's @GENFI1 conference in London to discuss biomarker development, ongoing trials and other advances related to genetic #FTD. Thanks to @jonrohrer for organizing and inviting us to join the conversation.
2
8
Today we announced positive Phase 1 results supporting continued clinical development of RDN-929, a potent and selective HDAC-CoREST inhibitor, for the treatment of #synaptopathies. Learn more here: rodintherapeutics.com/press_…
6
6
16